ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Drug Manufacturers - Specialty & Generic

Healthcare
$71.47 -1.76%

-$1.42 today

Market cap
$1.62B
Beta
0.44
P/E (TTM)
18.5
EPS (TTM)
$4.29
52W Low $62.61High $99.50

Volume 0.29M

Average 0.35M

ANIP EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

ANI Pharmaceuticals, Inc.NASDAQ: ANIP

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA grows, but more slowly than its trailing trend

Q1 FY2026 EBITDA of $57.37M rose 18.6% year over year, behind the +251.0% change in trailing-twelve-month EBITDA. Sequentially, it fell 25.4% from the prior quarter. Over 3 fiscal years it compounded at +102.3% a year.

Context

  • EBITDA amounted to 23.5% of revenue in FY2025, up 13.2 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of $350.65M (+69.2%) for the fiscal year ending Dec 2026, a slowdown from the +228.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$57.37M-25.4% QoQ
Last fiscal yearDec 2025
$207.27M+228.4% YoY
LTMMar 2026
$234.71M+251.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.6%+96.2%+77.6 pp
1 year+228.4%+69.2%-159.2 pp
3-year CAGR+102.3%+23.9%-78.4 pp
5-year CAGR+14.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
207.27M USD
Year-over-year change
+228.4%
4-year CAGR
+185.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ANIP compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +251.0% is the 2nd highest of 10, against a peer median of +11.7%.
  • EBITDA amounts to 25.4% of revenue for ANIP, versus a peer median of 17.4%.
ANIP Competitors
EBITDA for ANIP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹53.96B INR-45.2%+3.8%16.3%
VTRSViatris Inc.LTM Jun 2026$2.72B USD+650.7%—18.4%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$2.59B USD-12.9%—15.0%
BHCBausch Health Companies Inc.LTM Jun 2026$2.05B USD-37.3%+3.4%18.9%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$652.2M USD+11.7%+11.1%20.9%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$609.91M USD+83.3%+32.3%76.6%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$234.71M USD+251.0%+102.3%25.4%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$191.41M USD-26.2%+13.3%26.6%
HROWHarrow Health, Inc.LTM Mar 2026$31.47M USD+78.4%—11.7%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$1.03M USD——0.8%
EOLSEvolus, Inc.LTM Mar 2026-$14.03M USD+53.2%—4.6%
Peer median (excluding ANIP) —+11.7%+11.1%17.4%

Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue216.14M316.39M486.82M614.38M883.37M
Cost of Revenue100.61M138.79M181.51M250.21M432.73M
Gross Profit115.53M177.6M305.3M364.17M450.64M
Gross Margin53.5%56.1%62.7%59.3%51.0%
Research & Development11.37M22.32M34.29M44.58M51.66M
Selling, General & Admin84.29M124.04M161.7M249.64M317.75M
Operating Expenses155.32M212.88M258.33M363.58M369.41M
Depreciation & Amortization47.25M59.65M59.79M67.73M91.42M
EBITDA3.12M25.04M106.6M63.12M207.27M
EBITDA Margin1.4%7.9%21.9%10.3%23.5%
Operating Income(39.79M)(35.28M)46.97M584K81.23M
Operating Margin-18.4%-11.2%9.6%0.1%9.2%
Interest Income00000
Interest Expense11.92M28.05M26.94M17.6M20.06M
Other Income / Expenses(16.27M)(27.38M)(27.1M)(22.8M)14.56M
Income Before Tax(56.06M)(62.67M)19.87M(22.21M)95.79M
Pre-Tax Margin-25.9%-19.8%4.1%-3.6%10.8%
Income Tax Expense(13.46M)(14.77M)1.09M(3.69M)17.45M
Net Income(42.6M)(47.9M)18.78M(18.52M)78.34M
Net Margin-19.7%-15.1%3.9%-3.0%8.9%
EPS (Basic)(3.40)(3.05)0.95(1.04)3.50
EPS (Diluted)(3.40)(3.05)0.94(1.04)3.32
Weighted Avg Shares12.6M16.26M18M19.32M20.05M
Weighted Avg Shares (Diluted)12.6M16.26M18.19M19.32M21.23M

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Intrinsic Alpha fair value

Locked

Current Price

$71.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.